Bristol Myers Squibb and Otsuka Pharmaceuticals are facing a growing multidistrict litigation (MDL), consisting of product liability claims alleging Abilify causes compulsive behavior, like gambling and spending.
One of the most recent Abilify lawsuits comes from a Florida man, alleging he sustained massive financial damages due to the drug’s treatment mechanism causing Abilify compulsive spending.
Plaintiff Randy B. claims he developed Abilify compulsive spending soon after starting his medication, and that he did not have such habits before starting the antipsychotic.
Randy also states that at no point during or after his prescription did Bristol Myers or Otsuka warn him or his physician against Abilify compulsive behaviors, making the companies liable for his financial damages.
According to the Abilify lawsuit, Randy had been prescribed the antipsychotic for typical treatment purposes in November 2003. Like many patients, Randy had been recommended Abilify by his physician for mood balancing purposes and had relied on the marketing statements provided in advertisements from Otsuka and Bristol Myers.
Due to its unique treatment mechanism, Abilify is considered an atypical psychotic; it is typically prescribed when other medications have failed. Abilify works by balancing the dopamine levels in the brain, which is the brain chemical for pleasure and reward sensations.
By manipulating dopamine levels, Abilify triggers happy feelings of elation and ideal mood balance in patients. However numerous injury…